Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ql1203
- Development stage
- Phase 3
- Lead developer
- Qilu Pharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
QL1203 is a biosimilar monoclonal antibody that targets the epidermal growth factor receptor (EGFR). It is developed by Qilu Pharmaceutical for the treatment of metastatic colorectal cancer. Mechanistically, it acts as an EGFR antagonist/modulator, inhibiting EGFR-mediated signaling pathways involved in tumor cell proliferation and survival. Preclinical and clinical studies have demonstrated its similarity to panitumumab (Vectibix), with comparable efficacy and safety profiles. The drug is administered intravenously and has been evaluated in combination with standard chemotherapy regimens such as mFOLFOX6 for first-line therapy in RAS wild-type metastatic colorectal cancer[1][2][3][5][9].
- Brand names
- Vectibix
- Other names
- QL 1203QL1203QL-1203
02
Targets
Beyond the preview
Go deeper on ql1203.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ql1203.